Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients

HIV Treatment Bulletin - Vol. 8, No. 10, October 2007

On 24 September 2007, maraviroc (trade name in Europe Celsentri) was approved in Europe for treatment-experienced patients who have CCR5-tropic HIV infection. Maraviroc is a CCR5 inhibitor manufactured by Pfizer with the trade name Celsentri in Europe and Selzentry in the US.

Maraviroc is the first member of a new class of oral HIV medicines (CCR5-antagonists) and works by blocking viral entry into human cells.

EU approval of maraviroc is based on 48-week data from the two ongoing double-blind, placebo-controlled MOTIVATE clinical trials, which showed that maraviroc plus optimised background therapy (OBT) provided substantially greater viral load reduction compared to patients receiving OBT alone.

Further details and product information are in the European Public Assessment Report on the web site of the European Medicines Agency.

Celsentri - EMEA European Public Assessment Report Open link in new window http://www.emea.europa.eu/humandocs/Humans/EPAR/celsentri/celsentri.htm

2007-10-10
IB070810-06

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.